Stockreport

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR r [Read more]